NTLA Intellia Therapeutics Inc
Company Analysis
Latest News
🟢 Intellia Therapeutics rises 5.2% — Biotech Sector Rallies on Positive Clinical Trial Data and Regulatory News
With Biotech (XBI) up 2.2%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is trading higher today, driven by a...
🔴 Intellia Therapeutics is trading 5% down amid a 2.08% drop in biotech stocks
Intellia Therapeutics is trading at $10.59, down 5.11%, amid a broader risk-off session and weakness in biotech stocks. - Available reporting surfaced no...
🟢 Intellia Therapeutics is trading 6.62% up in after-hours trading
Intellia Therapeutics is trading at $12.62, up 6.62% in after-hours trading; no verified company announcement or clearly linked catalyst for the October 20...
🔴 Intellia Therapeutics is trading 5% down today amid biotech-sector weakness
Intellia Therapeutics is trading 5.21% lower at $11.93, with biotech-sector weakness the clearest context identified, though no clear sector-wide catalyst has...
🟢 Intellia Therapeutics is trading 6.3% up in after-hours trading with no confirmed catalyst
Intellia Therapeutics is trading 6.3% up at $13.38 in an unexplained after-hours rebound, with no confirmed catalyst. - The stock closed at $12.58 on October...
🟢 Intellia Therapeutics is trading 5.7% up
Intellia Therapeutics is trading 5.73% higher at $12.38 on October 8, 2026; no clear company-specific catalyst explaining the rise was found in available...
🔴 Intellia Therapeutics is trading 5% down — cause unconfirmed
Intellia Therapeutics is trading at $11.73, down 5.13% on October 7, with the precise driver unconfirmed. - No company announcement specific to October 7...
🔴 Intellia Therapeutics is trading 5% down today amid biotech-sector weakness
Intellia Therapeutics is trading 5.02% lower at $12.11, with biotech-sector weakness providing context, though the precise cause is unconfirmed. - No company...
🟢 Intellia Therapeutics is trading 5% up with no clear catalyst identified
Intellia Therapeutics is trading 5.04% higher at $11.99 on September 29, 2026, with the reason for the session’s gain unclear. - The FDA accepted the lonvo-z...
🟢 Intellia Therapeutics is trading 6.69% up today in after-hours trading
Intellia Therapeutics is trading at $12.97, up 6.69% in after-hours trading, with no confirmed company-specific catalyst. - No new Intellia...
🔴 Intellia Therapeutics is trading 5.7% down today after Anthropic’s Claude identified a CRISPR-like enzyme system
Intellia Therapeutics is trading 5.7% down at $11.63 after Anthropic’s Claude identified a previously unknown enzyme system resembling CRISPR. - The discovery...
🔴 Intellia Therapeutics is trading 5.08% down today as Treasury yields pressured growth stocks
Intellia Therapeutics is trading 5.08% down at $12.04, with the decline apparently tied to broader risk-off trading and higher Treasury yields. - Stronger U.S....
🟢 Intellia Therapeutics rises 5.5% — Biotech Sector Rallies on Major AI Collaboration Deal and Positive Clinical News
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector is trading higher, driven by a...
🟢 Intellia Therapeutics is trading 11% up today as biotechnology stocks rally
Intellia Therapeutics is trading 11.09% up now at $12.76 as biotechnology stocks rally alongside improving broader-market risk appetite. - No new...
🟢 Intellia Therapeutics is trading 5% up today amid broader biotechnology strength
Intellia Therapeutics is trading 5.4% up at $12.13, primarily linked to broader biotechnology strength; no new company-specific announcement was identified on...
🔴 Intellia Therapeutics falls 5.1% — Biotech Sector Declines on Key Drug Trial Failure and Shifting Investor Sentiment
With Biotech (XBI) down 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
Intellia's CRISPR Therapy Lonvo-z Granted FDA Priority Review for Hereditary Angioedema
Intellia Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for lonvoguran ziclumeran...
Intellia Gains FDA Priority Review for World’s First In Vivo CRISPR Therapy
Intellia Therapeutics announced the FDA accepted its Biologics License Application (BLA) for lonvoguran ziclumeran (lonvo-z). The agency granted Priority...
🟢 Intellia Therapeutics is trading 5% up in pre-market after announcing a $400 million non-dilutive loan facility
Intellia Therapeutics is trading $13.39 (+5.10%) after announcing a $400 million non-dilutive senior secured loan facility with OrbiMed. - $75 million was...
Intellia Therapeutics Secures up to $400 Million Non-Dilutive Debt Facility with OrbiMed
Intellia Therapeutics entered into a five-year senior secured credit facility with OrbiMed, providing up to $400 million in non-dilutive financing. The...